| Generic name | Liposomal doxorubicin |
| Pronunciation | Lip-SOH-mal dok-soh-ROO-bi-sin |
| Brand name(s), other common name(s) | Doxil® |
| Drug type | Antitumor antibiotic |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Liposomal doxorubicin is FDA approved for use in combination with bortezomib to treat patients with myeloma who have not previously received bortezomib and have received at least one prior therapy. See the FDA announcement about drug shortage of Doxil.
Side effects needing medical attention
Loss of appetite (or weight loss); nausea; vomiting; stomach pain; diarrhea; constipation; unusual tiredness or weakness; dizziness; hair loss; nosebleed; red or orange discoloration of urine; sores in the mouth and throat; tingling, burning, redness, swelling, peeling or flaking, blisters, or sores on the palms of the hands or soles of the feet; pain, itching, redness, swelling, blisters, or sores in the place where the medication was injected.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.